Add to ORKGBackground: The aim of this study was to evaluate whether docetaxel (taxotere) treatment with or without irinotecan improved patient outcomes with similar toxicity in recurrent non-small-cell lung cancer (NSCLC). Patients and methods: Patients with recurrent platinum-refractory NSCLC with Eastern Coopera-tive Oncology Group performance status of 0–2 were randomized to either docetaxel 30 mg/m2 an
Aim of this study was to evaluate activity and toxicity of docetaxel and carboplatin as second-tine ...
BACKGROUND: The role of salvage chemotherapy in advanced non-small cell lung cancer (NSCLC) is stil...
Response rate and toxicity of second-line therapy with docetaxel (75 mg m(-2)) or docetaxel, irinote...
In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced no...
To date, no combination regimen has proven superior to single agent chemotherapy as a second-line tr...
IntroductionThe ability of doublet therapy in the second-line setting in patients with platinum-refr...
To evaluate the efficacy and tolerance of the irinotecan plus docetaxel combination in patients with...
Smmmary In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with adv...
BackgroundThe survival impact of single-agent treatment with docetaxel, the standard regimen for rel...
BackgroundSequential administration of platinum-based doublet therapy and then a taxane may reduce t...
therapy for patients with non- small cell lung cancer after the failure of platinum- containing regi...
Background: This Phase II study was conducted to evaluate the efficacy and toxicity of weekly doceta...
PURPOSE: This Phase II study was undertaken to define the efficacy and toxicity of the combination o...
IntroductionTo evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in p...
The purpose of this study was to evaluate the efficacy and safety of docetaxel as first- and second-...
Aim of this study was to evaluate activity and toxicity of docetaxel and carboplatin as second-tine ...
BACKGROUND: The role of salvage chemotherapy in advanced non-small cell lung cancer (NSCLC) is stil...
Response rate and toxicity of second-line therapy with docetaxel (75 mg m(-2)) or docetaxel, irinote...
In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced no...
To date, no combination regimen has proven superior to single agent chemotherapy as a second-line tr...
IntroductionThe ability of doublet therapy in the second-line setting in patients with platinum-refr...
To evaluate the efficacy and tolerance of the irinotecan plus docetaxel combination in patients with...
Smmmary In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with adv...
BackgroundThe survival impact of single-agent treatment with docetaxel, the standard regimen for rel...
BackgroundSequential administration of platinum-based doublet therapy and then a taxane may reduce t...
therapy for patients with non- small cell lung cancer after the failure of platinum- containing regi...
Background: This Phase II study was conducted to evaluate the efficacy and toxicity of weekly doceta...
PURPOSE: This Phase II study was undertaken to define the efficacy and toxicity of the combination o...
IntroductionTo evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in p...
The purpose of this study was to evaluate the efficacy and safety of docetaxel as first- and second-...
Aim of this study was to evaluate activity and toxicity of docetaxel and carboplatin as second-tine ...
BACKGROUND: The role of salvage chemotherapy in advanced non-small cell lung cancer (NSCLC) is stil...
Response rate and toxicity of second-line therapy with docetaxel (75 mg m(-2)) or docetaxel, irinote...